Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2021

View Archived Issues

Kyoto University develops sequence-selective mitochondrial DNA alkylators for mitochondrial diseases

Pelareorep shows synergistic effect with radiotherapy in basal-like breast cancer

Dual SYK/VEGFR2 inhibitors discovered at Ocumension Therapeutics

Sichuan Kelun-Biotech Biopharmaceutical presents new PPAR receptor agonists

Fochon Pharmaceuticals describes CDK2/CDK4/CDK6 inhibitors

New necroptosis inhibitors synthesized at Anaxis Pharma

DIO2 as a new promising prognostic biomarker for patients with early-stage NSCLC

Identification of genomic correlates of clinical outcomes in metastatic uveal melanoma

IL2RA is a prognostic immune marker in epithelial ovarian cancer

STING agonists show preclinical promise for glioblastoma and pancreatic cancer therapy

New osteoarthritis risk variants and drug targets identified in large GWAS meta-analysis

Discovery of novel BRAF dimer inhibitors with promising efficacy

Seneca launches cancer gene delivery platform based on SVV-001 technology

Clearmind and Hebrew University partner on novel psychedelics

CMTA and Addex collaborate to investigate GABA-B PAMs for CMT1A

Theragnostics and AAA to jointly develop Ga-68 one-step PET radiopharmaceuticals

SNP in the CBS gene tied to overall survival in patients with NSCLC

Novel OSBPL7-targeting compounds show therapeutic efficacy in models of renal disease

Mosaic licenses rights to novel vaccine candidates from UC San Diego

Synthetic queuine STL-101 shows neuroprotective potential

Inhaled antibodies brought to SARS-CoV fight

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...